The year 2015 saw some significant developments in the medical field. One was the FDA decision to ban trans fats in food. The FDA also approved two new drugs: flibanserin (Addyi) to improve sexual function in premenopausal women, and alirocumab (Praluent), the first cholesterol-lowering treatment approved in a new class of drugs known as PCSK9 inhibitors. Results of several lifestyle studies also made headlines, including one study that found that women who had six healthy lifestyle habits were 92% less likely to develop heart disease than those who did not have these lifestyle habits.
To continue reading this article, you must login
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.